The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Cardiac Radiation Dose, Cardiac Disease, and Mortality in Patients With Lung Cancer
Open accessAbstract
BACKGROUND: Radiotherapy-associated cardiac toxicity studies in patients with locally advanced non-small cell lung cancer (NSCLC) have been limited by small sample size and nonvalidated cardiac endpoints. OBJECTIVES: The purpose of this analysis was to ascertain whether cardiac radiation dose is a predictor of major adverse cardiac events (MACE) and all-cause mortality (ACM). METHODS: This retrospective analysis included 748 consecutive locally advanced NSCLC patients treated with thoracic radiotherapy. Fine and Gray and Cox regressions were used to identify predictors for MACE and ACM, adjusting for lung cancer and cardiovascular prognostic factors, including pre-existing coronary heart disease (CHD). RESULTS: After a median follow-up of 20.4 months, 77 patients developed ≥1 MACE (2-year cumulative incidence, 5.8%; 95% confidence interval [CI]: 4.3% to 7.7%), and 533 died. Mean radiation dose delivered to the heart (mean heart dose) was associated with a significantly increased risk of MACE (adjusted hazard ratio [HR]: 1.05/Gy; 95% CI: 1.02 to 1.08/Gy; p < 0.001) and ACM (adjusted HR: 1.02/Gy; 95% CI: 1.00 to 1.03/Gy; p = 0.007). Mean heart dose (≥10 Gy vs. <10 Gy) was associated with a significantly increased risk of ACM in CHD-negative patients (178 vs. 118 deaths; HR: 1.34; 95% CI: 1.06 to 1.69; p = 0.014) with 2-year estimates of 52.2% (95% CI: 46.1% to 58.5%) versus 40.0% (95% CI: 33.5% to 47.4%); but not among CHD-positive patients (112 vs. 82 deaths; HR: 0.94; 95% CI: 0.70 to 1.25; p = 0.66) with 2-year estimates of 54.6% (95% CI: 46.8% to 62.7%) versus 50.8% (95% CI: 41.5% to 60.9%), respectively (p for interaction = 0.028). CONCLUSIONS: Despite the competing risk of cancer-specific death in locally advanced NSCLC patients, cardiac radiation dose exposure is a modifiable cardiac risk factor for MACE and ACM, supporting the need for early recognition and treatment of cardiovascular events and more stringent avoidance of high cardiac radiotherapy dose.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
The National Lung Screening Trial Research Team (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102873 · Cited by 11,064
General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study
D’Agostino, R. B., Vasan, R. S., Pencina, M. J., Wolf, P. A., Cobain, M., Massaro, J. M., & Kannel, W. B. (2008) · Circulation · doi:10.1161/circulationaha.107.699579 · Cited by 7,491
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer
Darby, S. C., Ewertz, M., McGale, P., Bennet, A. M., Blom-Goldman, U., Brønnum, D., Correa, C., Cutter, D., Gagliardi, G., Gigante, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209825 · Cited by 3,974
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845
Lung cancer: current therapies and new targeted treatments
Hirsch, F. R., Scagliotti, G. V., Mulshine, J. L., Kwon, R., Curran, W. J., Wu, Y.-L., & Paz-Ares, L. (2017) · The Lancet · doi:10.1016/s0140-6736(16)30958-8 · Cited by 3,283
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Kurata, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809697 · Cited by 2,798
Bradley, J. D., Paulus, R., Komaki, R., Masters, G., Blumenschein, G., Schild, S., Bogart, J., Hu, C., Forster, K., Magliocco, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71207-0 · Cited by 2,015
Armenian, S. H., Lacchetti, C., Barac, A., Carver, J., Constine, L. S., Denduluri, N., Dent, S., Douglas, P. S., Durand, J.-B., Ewer, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.5400 · Cited by 1,290
Feng, M., Moran, J. M., Koelling, T., Chughtai, A., Chan, J. L., Freedman, L., Hayman, J. A., Jagsi, R., Jolly, S., Larouere, J., et al. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.10.058 · Cited by 715
Hicks, K. A., Tcheng, J. E., Bozkurt, B., Chaitman, B. R., Cutlip, D. E., Farb, A., Fonarow, G. C., Jacobs, J. P., Jaff, M. R., Lichtman, J. H., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000156 · Cited by 704
Classification accuracy and cut point selection
Liu, X. (2012) · Statistics in Medicine · doi:10.1002/sim.4509 · Cited by 676
2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials
Hicks, K. A., Tcheng, J. E., Bozkurt, B., Chaitman, B. R., Cutlip, D. E., Farb, A., Fonarow, G. C., Jacobs, J. P., Jaff, M. R., Lichtman, J. H., et al. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.12.018 · Cited by 603
Cardiovascular Disease After Hodgkin Lymphoma Treatment: 40-Year Disease Risk
van Nimwegen, F. A., Schaapveld, M., Janus, C. P. M., Krol, A. D. G., Petersen, E. J., Raemaekers, J. M. M., Kok, W. E. M., Aleman, B. M. P., & van Leeuwen, F. E. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.1180 · Cited by 514
Chi-squared goodness-of-fit tests for the proportional hazards regression model
SCHOENFELD, D. (1980) · Biometrika · doi:10.1093/biomet/67.1.145 · Cited by 489
Gaynor, J. J., Feuer, E. J., Tan, C. C., Wu, D. H., Little, C. R., Straus, D. J., Clarkson, B. D., & Brennan, M. F. (1993) · Journal of the American Statistical Association · doi:10.1080/01621459.1993.10476289 · Cited by 483
van Nimwegen, F. A., Schaapveld, M., Cutter, D. J., Janus, C. P. M., Krol, A. D. G., Hauptmann, M., Kooijman, K., Roesink, J., van der Maazen, R., Darby, S. C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.4444 · Cited by 464
Senan, S., Brade, A., Wang, L.-H., Vansteenkiste, J., Dakhil, S., Biesma, B., Martinez Aguillo, M., Aerts, J., Govindan, R., Rubio-Viqueira, B., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8824 · Cited by 433
Wang, K., Eblan, M. J., Deal, A. M., Lipner, M., Zagar, T. M., Wang, Y., Mavroidis, P., Lee, C. B., Jensen, B. C., Rosenman, J. G., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.0229 · Cited by 428
Dess, R. T., Sun, Y., Matuszak, M. M., Sun, G., Soni, P. D., Bazzi, L., Murthy, V. L., Hearn, J. W. D., Kong, F.-M., Kalemkerian, G. P., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.6142 · Cited by 362
Rasmussen-Torvik, L. J., Shay, C. M., Abramson, J. G., Friedrich, C. A., Nettleton, J. A., Prizment, A. E., & Folsom, A. R. (2013) · Circulation · doi:10.1161/circulationaha.112.001183 · Cited by 302
Speirs, C. K., DeWees, T. A., Rehman, S., Molotievschi, A., Velez, M. A., Mullen, D., Fergus, S., Trovo, M., Bradley, J. D., & Robinson, C. G. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.09.134 · Cited by 282
Hoffmann, U., Massaro, J. M., D'Agostino, R. B., Kathiresan, S., Fox, C. S., & O'Donnell, C. J. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.003144 · Cited by 239
Self-citationPrevalence of Preexisting Cardiovascular Disease in Patients With Different Types of Cancer
Al-Kindi, S. G., & Oliveira, G. H. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.09.009 · Cited by 184
Hardy, D. S., Liu, C.-W., Cormier, J. N., Xia, R., & Du, X. L. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq042 · Cited by 140
2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials
Hicks, K. A., Tcheng, J. E., Bozkurt, B., CHAITMAN, B. R., Cutlip, D. E., Farb, A. A., Fonarow, G. C., Jacobs, J. P., Jaff, M. R., Lichtman, J. H., et al. (2015) · Journal of Nuclear Cardiology · doi:10.1007/s12350-015-0209-1 · Cited by 69
Cardiovascular Damage Associated With Chest Irradiation
Mrotzek, S. M., Rassaf, T., & Totzeck, M. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00041 · Cited by 50
Guberina, M., Eberhardt, W., Stuschke, M., Gauler, T. C., Heinzelmann, F., Cheufou, D. H., Kimmich, M., Friedel, G., Schmidberger, H., Darwiche, K., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx069 · Cited by 49
Planek, M. I. C., Silver, A. J., Volgman, A. S., & Okwuosa, T. M. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014668 · Cited by 39
Pursnani, A. K., Massaro, J. M., D’Agostino, R. B., O’Donnell, C. J., & Hoffmann, U. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3594 · Cited by 25
Self-citationCanada, J. M., THOMAS, G. K., Trankle, C. R., Carbone, S., Billingsley, H., Tassell, B. W. V., Evans, R. K., Garten, R. S., Weiss, E., & Abbate, A. (2020) · Cardio-Oncology · doi:10.1186/s40959-020-0058-1 · Cited by 24
Lu, M. T., Onuma, O. K., Massaro, J. M., D’Agostino, R. B., O’Donnell, C. J., & Hoffmann, U. (2016) · Circulation · doi:10.1161/circulationaha.116.023957 · Cited by 23
Self-citation
Cited by
Pudil, R., Mueller, C., Čelutkienė, J., Henriksen, P. A., Lenihan, D., Dent, S., Barac, A., Stanway, S., Moslehi, J., Suter, T. M., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.2017 · Cited by 357
Cardiac Toxicity of Thoracic Radiotherapy: Existing Evidence and Future Directions
Banfill, K., Giuliani, M., Aznar, M., Franks, K., McWilliam, A., Schmitt, M., Sun, F., Vozenin, M. C., & Faivre Finn, C. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.11.002 · Cited by 272
Metadata
- Authors
- Atkins, K. M., Rawal, B., Chaunzwa, T. L., Lamba, N., Bitterman, D. S., Williams, C. L., Kozono, D. E., Baldini, E. H., Chen, A. B., Nguyen, P. L., D’Amico, A. V., Nohria, A., Hoffmann, U., Aerts, H. J. W. L., & Mak, R. H.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 73
- Issue
- 23
- Pages
- 2976-2987
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2952155820
- Cited by
- 274
- References
- 38
- FWCI
- 21.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.